A U.S. Food & Drug Administration (FDA) panel recently recommended approval for AstraZeneca’s new monoclonal antibody, which supposedly protects infants and toddlers up to age 2 from respiratory syncytial virus (RSV).
The drug, manufactured by AstraZeneca and Sanofi, is designed to be given to infants in a single shot at birth or just before the start of a baby’s first RSV season.
It can also be given in a larger dose in a second RSV season in children who are highly vulnerable.
Read Full Article Here…(wltreport.com)
Home | Caravan to Midnight (zutalk.com)
Live Stream + Chat (zutalk.com)
